Overview
BPC-157 is a pentadecapeptide (15 amino acids) derived from human gastric juice. It has been extensively studied for its regenerative properties, particularly in healing tendons, ligaments, muscles, and the gastrointestinal tract. It is one of the most popular peptides in the biohacking community.
Mechanism of action
BPC-157 upregulates growth hormone receptors, promotes angiogenesis (new blood vessel formation), and modulates the nitric oxide system. It activates the FAK-paxillin signaling pathway, which is critical for cell migration and tissue repair. It also exhibits cytoprotective effects on the gastrointestinal mucosa.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| injury recovery | subcutaneous | 250–500 mcg | twice daily | Inject near injury site. 4-8 week cycles. |
| gut healing | oral | 250–500 mcg | twice daily | Take on empty stomach. 4-8 week cycles. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Over 100 preclinical studies demonstrate efficacy in wound healing, tendon repair, bone healing, and gut protection. No human clinical trials have been completed as of 2026. Rat studies show accelerated healing of transected Achilles tendons by 72%, reduced inflammation markers, and protection against NSAID-induced gastropathy.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with BPC-157 for synergistic effects.
Legal status
One of 14 peptides under FDA reclassification review (RFK Jr. initiative). Previously available from research chemical suppliers; most US vendors ceased sales in 2025-2026.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings. Supplier listings will be available if FDA reclassification is formalized.